ETIOPATHOGENETIC TREATMENT OF INFLUENZA AND ARVI IN CHILDREN: A NEW LOOK AT THE OLD PROBLEM

ETIOPATHOGENETIC TREATMENT OF INFLUENZA AND ARVI IN CHILDREN: A NEW LOOK AT THE OLD PROBLEM

O. V. Shamsheva

A new value was acquired by the drug Orvirem®, which is a combination of rimantadine and natrium alginate. In recent years, it has not been recommended for use due to the resistance to it strains of the influenza A(H1N1) virus pdm2009. Currently, this drug has acquired a new meaning, and this is due to the dominance of subtype A(H3N2). Two recent clinical studies have demonstrated that the drug Orvirem® has proven activity against viruses not only of influenza A but also B, coronavirus, and other common pathogens of respiratory viral infections (rhinoviruses, respiratory syncytial virus, adenovirus, etc.). High efficacy, safety and absence of adverse reactions make it possible to widely use Orvirem® in children from the first year of life, incl. with chronic diseases.

2017

antiviral drugs, Respiratory viruses, acute respiratory viral infections (arvi), influenza, rimantadine

DOI: 10.22627/2072-8107-2017-16-3-49-54

Detskie Infekcii (Moskva)

LLC Diagnostics and Vaccines""

Pediatrics

RU